<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425565</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/17/0672</org_study_id>
    <nct_id>NCT03425565</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancers</brief_title>
  <acronym>PEACOCC</acronym>
  <official_title>A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to
      determine whether treatment with pembrolizumab is effective in patients with advanced clear
      cell gynaecological cancers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Clear Cell Tumor</condition>
  <condition>Gynecologic Cancer</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>3 weekly cycles of Pembrolizumab administered by IV</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological diagnosis of advanced clear cell ovarian (including primary peritoneal
             and fallopian tube), endometrial, vaginal, vulval or cervical cancer.

          2. Have measurable disease based on RECIST 1.1.

          3. Evidence of radiological disease progression

          4. Patient is willing to provide tissue from a newly obtained core or excisional biopsy
             of a tumour lesion at baseline, 6-8 weeks after start of treatment and at the time of
             progression

          5. ECOG Performance Status 0 or 1

          6. Patient has a life expectancy of at least 3 months from consent

          7. Received â‰¥ 1 line of prior chemotherapy

        Exclusion Criteria:

          1. Has a known diagnosis of immunodeficiency or is receiving systemic steroid therapy at
             doses &gt; 10mg prednisolone daily or equivalent or any other form of immunosuppressive
             therapy within 7 days prior to the first dose of trial treatment.

          2. Has a known history of active TB (Bacillus Tuberculosis), Hepatitis B (e.g., HBsAg
             reactive), Hepatitis C or a known history of Human Immunodeficiency Virus (HIV)

          3. Has symptomatic central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          4. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids (at a dose &gt;10mg
             predisolone daily or equivalent) or immunosuppressive drugs).

          5. Has known history or evidence of active, non-infectious pneumonitis.

          6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

          7. Has received a live vaccine within 30 days prior to the planned start of trial
             treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Hughes</last_name>
    <phone>+44 (0)207 679 9284</phone>
    <email>ctc.peacocc@ucl.ac.uk</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

